1. An isolated polynucleotide comprising s sequence selected from the group consisting of: (a) a sequence provided in SEQ ID NO: 347; (b) complements of the sequences provided in SEQ ID NO: 347; (c) a polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 347 or a portion thereof; and (d) degenerate variants of a sequence provided in SEQ ID NO: 347. 2. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) an amino acid sequence encoded by the polynucleotide of claim 1; (b) the amino acid sequence set forth in SEQ ID NO: 348; (c) an amino acid sequence having at least 70% identity to the amino acid sequence set forth in SEQ ID NO: 348; and (d) an amino acid sequence having at least 90% identity to the amino acid sequence set forth in SEQ ID NO: 348; wherein said polypeptide can be used for the detection of lung cancer. 3. An expression vector comprising a polynucleotide of claim 1 operably linked to an expression control sequence. 4. A host cell transformed or transfected with an expression vector according to claim 3. 5. An isolated antibody, or antigen-binding fragment thereof, that specifically binds to a polypeptide of claim 2. 6. A method for detecting the presence of a cancer in a patient, comprising the steps of: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with a binding agent that binds to a polypeptide selected from the group consisting of: i. a polypeptide of claim 2; ii. the polypeptide set forth in SEQ ID NO:176; iii. a polypeptide having at least 70% identity to the polypeptide set forth in SEQ ID NO:176; and iv. a polypeptide having at least 90% identity to the polypeptide set forth in SEQ ED NO:176; (c) detecting in the sample an amount of polypeptide that binds to the binding agent; and (d) comparing the amount of polypeptide to a predetermined cut-off value and therefrom determining the presence of a cancer in the patient. 7. A fusion protein comprising at least one polypeptide according to claim 2 and an unrelated sequence, wherein said fusion protein can be used for the detection of lung cancer. 8. An oligonucleotide that hybridizes to a sequence recited in SEQ ID NOs: 175 and 347 under highly stringent conditions. 9. A method for stimulating and/or expanding T cells specific for a tumor protein, comprising contacting T cells with at least one component selected from the group consisting of: (a) polypeptides according to claim 2; (b) the polypeptide set forth in SEQ ID NO: 176; (c) a polypeptide having at least 70% identity to the polypeptide set forth in SEQ ID NO:176; (d) a polypeptide having at least 90% identity to the polypeptide set forth in SEQ ID NO: 176; (e) polynucleotides according to claim 1; (t) thcpolynucleotidcsetforthinSEQIDNO:175 (g) a polynucleotide having at least 70% identity to the polynucleotide set forth in SEQ ID NO: 175; (h) a polynucleotide having at least 90% identity to the polynucleotide set forth in SEQ ID NO: 175; and (i) antigen-presenting cells that express a polynucleotide according to claim 1 or parts (f), (g), or (h); under conditions and for a time sufficient to permit the stimulation and/or expansion of T cells. 10. An isolated T cell population, comprising T cells prepared according to the method of claim 9. 11. A composition comprising a first component selected from the group consisting of physiologically acceptable carriers and immunostimulants, and a second component selected from the group consisting of: (a) polypeptides according to claim 2; (b) polynucleotides according to claim 1; (c) antibodies according to claim 5; (d) fusion proteins according to claim 7; (e) T cell populations according to claim 10; and (f) antigen presenting cells that express a polypeptide selected from the group consisting of a polypeptide according to claim 2, the polypeptide set forth in SEQ ID NO: 176, a polypeptide having at least 70% identity to the polypeptide set forth in SEQ ID NO-.176, and a polypeptide having at least 90% identity to the polypeptide set forth in SEQ ID NO: 176. 12. The composition according to claim 11 for use in inducing an immune response in a patient. 13. The composition according to claim 11 for use in treating lung cancer in a patient. 14. A method for determining the presence of a cancer in a patient, comprising the steps of: (a) obtaining a biological sample from the patient; (b) contacting the biological sample with an oligonucleotide according to claim 8; (c) detecting in the sample an amount of a polynucleotide that hybridizes to the oligonucleotide; and (d) comparing the amount of polynucleotide that hybridizes to the oligonucleotide to a predetermined cut-off value, and therefrom determining the presence of the cancer in the patient. 15. A diagnostic kit comprising at least one oligonucleotide according to claim 8. 16. A diagnostic kit comprising at least one antibody according to claim 5 and a detection reagent, wherein the detection reagent comprises a reporter group. 17. A method for inhibiting the development of lung cancer in a patient, the method comprising the steps of: (a) incubating CD4+ and/or CD8+ T cells isolated from a patient with at least one component selected from me group consisting of: (i) polypeptides according to claim 2; (ii) polynucleotides according to claim 1; (iii) the polypeptide set forth in SEQ ID NO:176; (iv) the polynucleotide set forth in SEQ ID NO:175; and (v) antigen presenting cells mat express a polypeptide of claim 2 or the polypeptide set forth in SEQ ID NO:176, such that T cell proliferate; (b) administering to the patient an effective amount of the proliferated T cells, and thereby inhibiting development of a cancer in the patient.